Summary
ADB-FUBICA is a pharmaceutical compound that exerts substantial agonistic effects on cannabinoid receptors, displaying EC50 values of 2.6 nM at CB1 and 3.0 nM at CB2.
| Identifiers | |
|---|---|
| IUPAC name | |
| CAS Number | 1801338-23-7 |
|---|---|
| UNII | S3ABP24K72 |
| Chemical and physical data | |
| Formula | C22H24FN3O2 |
| Molar mass | 381.451 g·mol−1 |
FAQ
1. What is ADB-FUBICA?
ADB-FUBICA is a chemical compound that functions as a potent agonist for cannabinoid receptors. It has drawn attention for its potential pharmacological effects.
2. What are cannabinoid receptors?
Cannabinoid receptors are a part of the endocannabinoid system in the human body. They are crucial in regulating various physiological processes, including mood, appetite, and pain sensation.
3. How does ADB-FUBICA interact with cannabinoid receptors?
ADB-FUBICA acts as an agonist, meaning it binds to and activates cannabinoid receptors, particularly CB1 and CB2, leading to various physiological effects.
4. What are the EC50 values for ADB-FUBICA at CB1 and CB2 receptors?
ADB-FUBICA demonstrates its potency with an EC50 of 2.6 nM at CB1 and 3.0 nM at CB2 receptors. These values indicate its effectiveness in stimulating these receptors.
5. What are the potential effects of ADB-FUBICA use?
The specific effects of ADB-FUBICA can vary but may include alterations in mood, perception, and other physiological responses due to its interaction with cannabinoid receptors.
6. Is ADB-FUBICA legal and safe for use?
The legal status of ADB-FUBICA varies by region and country. Its safety is a subject of concern, as the use of synthetic cannabinoids can have unpredictable and potentially harmful effects. Users should be aware of and adhere to local regulations.
7. Can ADB-FUBICA be used for medical purposes?
ADB-FUBICA is primarily recognized as a research chemical and not for medical use. Its potential therapeutic applications still need to be established.
8. What are the risks associated with ADB-FUBICA use?
Using synthetic cannabinoids like ADB-FUBICA can pose various risks, including potential health hazards, unknown long-term effects, and possible legal consequences.
9. Where can I find more information about ADB-FUBICA?
For comprehensive information about ADB-FUBICA, consider referring to scientific literature, research studies, and relevant authorities. It’s crucial to stay informed about the latest developments.
10. How can I seek help for substance abuse or addiction related to synthetic cannabinoids?
If you or someone you know is struggling with substance abuse or addiction, numerous organizations and resources are available to provide assistance and support. Seek help from addiction treatment centres or support groups for guidance.
References
- In September 2015, Banister SD, Moir M, Stuart J, Kevin RC, Wood KE, Longworth M, and their research team conducted a comprehensive study delving into the “Pharmacology of Indole and Indazole Synthetic Cannabinoid Designer Drugs.” The study encompassed a range of compounds including AB-FUBINACA, ADB-FUBINACA, AB-PINACA, ADB-PINACA, 5F-AB-PINACA, 5F-ADB-PINACA, ADBICA, and 5F-ADBICA. Their findings were published in Volume 6, Issue 9 of “ACS Chemical Neuroscience,” spanning pages 1546–1559. For further details, you can refer to doi:10.1021/acschemneuro.5b00112. The PMID for this publication is 26134475.
- Moving to November 2015, Qian Z, Hua Z, Liu C, and Jia W conducted a noteworthy investigation that led to the identification of “Four types of cannabimimetic indazole and indole derivatives.” These compounds, namely ADB-BINACA, AB-FUBICA, ADB-FUBICA, and AB-BICA, were recognized as new psychoactive substances. The research was published in “Forensic Toxicology,” specifically in Issue 34, covering pages 133–143. You can access their study via doi:10.1007/s11419-015-0297-2, and it is also available on PMC (PubMed Central) with the identifier PMC 4705129. The PMID for this publication is 26793280.